Target intelligence / Profile preview

A20 B-cell lymphoma idiotype

Molecular classification
Immunoglobulin variable region, B-cell receptor idiotype
01

Overview

The A20 B-cell lymphoma idiotype refers to the unique antigenic determinant formed by the variable regions of the immunoglobulin heavy and light chains expressed on the surface of A20 cells, a widely used murine model of diffuse large B-cell lymphoma (DLBCL). This idiotype arises from somatic hypermutation (SHM) in IgV genes during B-cell development in germinal centers, producing high-affinity antigen-binding sites.[1] In A20 lymphoma, it functions as part of the B-cell receptor (BCR), enabling chronic antigen-driven signaling that contributes to lymphomagenesis, often alongside NF-κB pathway dysregulation such as A20 (TNFAIP3) inactivation.[1] The idiotype serves as a tumor-specific antigen, potentially targetable for immunotherapy, though no approved drugs are noted; it exemplifies post-germinal center B-cell derivation marked by hypermutated IgV genes.[1][3]

Other names
Immunoglobulin heavy and light chain variable region idiotype of A20A20 idiotypeA20 IgV idiotype
02

Biological functions

Antigen recognitionB-cell receptor signalingImmune response
03

Disease associations

CancerB-cell lymphoma

Beyond the preview

Go deeper on A20 B-cell lymphoma idiotype.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on A20 B-cell lymphoma idiotype.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call